Protease nexin-1 inhibitor for the treatment of haemorrhagic disease

The thrombogram of FVIII-KO mice displays a prolonged time to peak and a reduced peak thrombin. The addition of the neutralizing anti-protease nexin-1 (PN-1) antibody enhances thrombin generation in PRP from haemophilia mice. The thrombogram of patient with haemophilia displays prolonged lag time and time to peak and a reduced peak thrombin and a reduced endogenous thrombin potential. As observed with the addition of recombinant FVIII, the neutralizing anti-PN-1 antibody enhances thrombin generation in PRP from patients with haemophilia A. Anti-PN-1 antibody improves thrombin generation in mild and moderate haemophilia patients but not in severe haemophilia patients. These findings establish a requirement for PN-1 inhibition as a specific anticoagulant in platelets and demonstrated that blocking PN-1 have a role in haemorrhagic disease treatment.

Keywords: Protease nexin-1, Haemophilia
Patent Application number: European Procedure (Patents) (EPA) - 13 Avr. 2015 - 15 305 544.7
Inventors:
LENTING PetrusDENIS CécileCHRISTOPHE Olivier
Publications:
null

Reference:

BIO15008-T1

    Business Developper
    contact
    Aymeric Empereur
    Business Developer
    Patent filling date: 15-04-2015
    Rare disease: Yes
    Second indication: No

    You might also be interested in